statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024...

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with...

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 PR...

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus...

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 PR...

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA...

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility PR Newswire GAITHERSBURG, Md., April 3, 2024 GAITHERSBURG...

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

YS Biopharma Co., Ltd. (NASDAQ:YS - Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 116,800 shares...

YS Biopharma Co., Ltd. (NASDAQ:YS) Short Interest Down 51.6% in March

YS Biopharma Co., Ltd. (NASDAQ:YS  Get Free Report)s stock price traded down 3.1% during mid-day trading on Tuesday . The company traded as low as $0.58 and last traded at $0.63...

YS Biopharma (NASDAQ:YS) Trading Down 3.1%

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries...

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

YS Biopharma Co. Ltd. engages in discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

Watchers	1,182
52-Wk Low	$0.3503
52-Wk High	$1.78

Volume	170,929.00
52-Wk High	$1.78
52-Wk Low	$0.3503

YS YS Biopharma Co Ltd

About

Feed

News

Fundamentals